| 1 |
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections |
Gram-negative Bacterial Infections |
Drug: ATM-AVI|Drug: BAT |
Pfizer |
Phase 2 |
NCT05639647 |
2023-04-18 |
| 2 |
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia |
Drug: Nemtabrutinib|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Bendamustine|Biological: Rituximab|Biological: Truxima|Biological: Ruxience|Biological: Riabni |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05624554 |
2023-03-16 |
| 3 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma |
Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone |
AbbVie|Genmab |
Phase 3 |
NCT05578976 |
2023-02-08 |
| 4 |
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥0% (MK-3475-D46) |
Carcinoma, Non-Small-Cell Lung |
Biological: Sacituzumab Govitecan|Biological: Pembrolizumab |
Merck Sharp & Dohme LLC|Gilead Sciences |
Phase 3 |
NCT05609968 |
2023-02-06 |
| 5 |
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B |
Hemophilia A|Hemophilia B |
Drug: marstacimab |
Pfizer |
Phase 3 |
NCT05611801 |
2022-12-09 |
| 6 |
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia |
Anemia |
Biological: Luspatercept|Drug: Placebo|Other: Best Supportive Care |
Bristol-Myers Squibb |
Phase 2 |
NCT05664737 |
2022-12-09 |
| 7 |
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
Atopic Dermatitis |
Drug: Upadacitinib|Drug: Dupilumab |
AbbVie |
Phase 3 |
NCT05601882 |
2022-11-28 |
| 8 |
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Non Small Cell Lung Cancer |
Biological: Telisotuzumab Vedotin |
AbbVie |
Phase 2 |
NCT05513703 |
2022-11-21 |
| 9 |
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) |
Pneumococcal Disease |
Biological: V116|Biological: PPSV23 |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05569954 |
2022-11-07 |
| 10 |
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) |
Hodgkin Lymphoma |
Biological: favezelimab/pembrolizumab|Drug: bendamustine|Drug: gemcitabine |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05508867 |
2022-10-18 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.